Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Clinical Outcomes With the Use of Prophylactic Versus Therapeutic Anticoagulation in COVID-19

Jishu K. Motta, Rahila O. Ogunnaike, Rutvik Shah, Stephanie Stroever, Harold V. Cedeño, Shyam K. Thapa, John J. Chronakos, Eric J. Jimenez, Joann Petrini, Abhijith Hegde
doi: https://doi.org/10.1101/2020.07.20.20147769
Jishu K. Motta
1Department of Medicine, Danbury Hospital, Danbury, CT
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: jishu.motta@nuvancehealth.org
Rahila O. Ogunnaike
1Department of Medicine, Danbury Hospital, Danbury, CT
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Rutvik Shah
1Department of Medicine, Danbury Hospital, Danbury, CT
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Stephanie Stroever
2Department of Research and Innovation, Danbury Hospital/ Nuvance Health Network, Danbury, CT
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Harold V. Cedeño
1Department of Medicine, Danbury Hospital, Danbury, CT
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Shyam K. Thapa
1Department of Medicine, Danbury Hospital, Danbury, CT
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
John J. Chronakos
3Department of Pulmonary and Critical Care, Danbury Hospital, Danbury, CT
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Eric J. Jimenez
3Department of Pulmonary and Critical Care, Danbury Hospital, Danbury, CT
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Joann Petrini
2Department of Research and Innovation, Danbury Hospital/ Nuvance Health Network, Danbury, CT
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Abhijith Hegde
3Department of Pulmonary and Critical Care, Danbury Hospital, Danbury, CT
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Supplementary material
  • Data/Code
  • Preview PDF
Loading

Abstract

Background This study is the first of its kind to assess the impact of preemptive therapeutic dose anticoagulation on mortality compared to prophylactic anticoagulation among COVID-19 patients. Its findings provide insight to clinicians regarding the management of COVID-19, particularly with the known prothrombotic state.

Research Question To determine the impact of anticoagulation on in-hospital mortality among COVID-19 positive patients with the a priori hypothesis that there would be a lower risk of in-hospital mortality with use of preemptive therapeutic over prophylactic dose enoxaparin or heparin.

Study Design Retrospective cohort study from April 1 - April 25, 2020. The date of final follow-up was June 12, 2020.

Setting Two large, acute care hospitals in Western Connecticut.

Participant Five hundred and one inpatients were identified after discharge as 18 years or older and positive for SARS-CoV-2. The final sample size included 374 patients after applying exclusion criteria. Demographic variables were collected via hospital billing inquiries, while the clinical variables were abstracted from patients’ medical records.

Exposure Preemptive enoxaparin or heparin at a therapeutic or prophylactic dose.

Main Outcom In-hospital mortality.

Results When comparing preemptive therapeutic to prophylactic anticoagulation through multi-variable analysis, risk of in-hospital mortality was 2.3 times greater in patients receiving preemptive therapeutic anticoagulation (95% CI = 1.0, 4.9; p = 0.04).

Interpretation An increase in in-hospital mortality was observed with preemptive therapeutic anticoagulation. Thus, in the management of COVID-19 and its complications, we recommend further research and cautious use of preemptive therapeutic over prophylactic anticoagulation.

Competing Interest Statement

The authors have declared no competing interest.

Funding Statement

No external funding was received

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

The protocol and subsequent work were granted exempt status by the Biomedical Research Alliance of New York (BRANY) Institutional Review Board under category #4(iii), as detailed in 45 CFR 46.104(d) and BRANYs Standard Operating Procedure.

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Footnotes

  • No conflicts exist for the specified authors

  • Funding information: No external funding was received.

Data Availability

Data analyzed in this manuscript is available upon request from the corresponding author, Jishu Kaul Motta, at jishu.motta{at}nuvancehealth.org

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Back to top
PreviousNext
Posted July 26, 2020.
Download PDF

Supplementary Material

Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Clinical Outcomes With the Use of Prophylactic Versus Therapeutic Anticoagulation in COVID-19
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Clinical Outcomes With the Use of Prophylactic Versus Therapeutic Anticoagulation in COVID-19
Jishu K. Motta, Rahila O. Ogunnaike, Rutvik Shah, Stephanie Stroever, Harold V. Cedeño, Shyam K. Thapa, John J. Chronakos, Eric J. Jimenez, Joann Petrini, Abhijith Hegde
medRxiv 2020.07.20.20147769; doi: https://doi.org/10.1101/2020.07.20.20147769
Digg logo Reddit logo Twitter logo Facebook logo Google logo LinkedIn logo Mendeley logo
Citation Tools
Clinical Outcomes With the Use of Prophylactic Versus Therapeutic Anticoagulation in COVID-19
Jishu K. Motta, Rahila O. Ogunnaike, Rutvik Shah, Stephanie Stroever, Harold V. Cedeño, Shyam K. Thapa, John J. Chronakos, Eric J. Jimenez, Joann Petrini, Abhijith Hegde
medRxiv 2020.07.20.20147769; doi: https://doi.org/10.1101/2020.07.20.20147769

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Cardiovascular Medicine
Subject Areas
All Articles
  • Addiction Medicine (216)
  • Allergy and Immunology (495)
  • Anesthesia (106)
  • Cardiovascular Medicine (1096)
  • Dentistry and Oral Medicine (196)
  • Dermatology (141)
  • Emergency Medicine (274)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (500)
  • Epidemiology (9767)
  • Forensic Medicine (5)
  • Gastroenterology (480)
  • Genetic and Genomic Medicine (2308)
  • Geriatric Medicine (222)
  • Health Economics (462)
  • Health Informatics (1559)
  • Health Policy (735)
  • Health Systems and Quality Improvement (603)
  • Hematology (236)
  • HIV/AIDS (503)
  • Infectious Diseases (except HIV/AIDS) (11641)
  • Intensive Care and Critical Care Medicine (617)
  • Medical Education (237)
  • Medical Ethics (67)
  • Nephrology (257)
  • Neurology (2142)
  • Nursing (134)
  • Nutrition (336)
  • Obstetrics and Gynecology (427)
  • Occupational and Environmental Health (517)
  • Oncology (1176)
  • Ophthalmology (364)
  • Orthopedics (128)
  • Otolaryngology (220)
  • Pain Medicine (146)
  • Palliative Medicine (50)
  • Pathology (311)
  • Pediatrics (695)
  • Pharmacology and Therapeutics (300)
  • Primary Care Research (267)
  • Psychiatry and Clinical Psychology (2180)
  • Public and Global Health (4657)
  • Radiology and Imaging (778)
  • Rehabilitation Medicine and Physical Therapy (457)
  • Respiratory Medicine (623)
  • Rheumatology (274)
  • Sexual and Reproductive Health (225)
  • Sports Medicine (210)
  • Surgery (251)
  • Toxicology (43)
  • Transplantation (120)
  • Urology (94)